Ameriprise’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$818K Sell
187,270
-15,046
-7% -$71K ﹤0.01% 3393
2025
Q4
$1.02M Sell
202,316
-126,307
-38% -$586K ﹤0.01% 3317
2025
Q3
$1.14M Sell
328,623
-83,688
-20% -$314K ﹤0.01% 3298
2025
Q2
$1.4M Buy
412,311
+134,963
+49% +$450K ﹤0.01% 3123
2025
Q1
$1.11M Buy
277,348
+27,980
+11% +$145K ﹤0.01% 3170
2024
Q4
$1.62M Sell
249,368
-104,073
-29% -$620K ﹤0.01% 3035
2024
Q3
$1.96M Buy
353,441
+85,805
+32% +$487K ﹤0.01% 2928
2024
Q2
$1.49M Sell
267,636
-21,920
-8% -$132K ﹤0.01% 2995
2024
Q1
$1.94M Sell
289,556
-10,196
-3% -$80.6K ﹤0.01% 2885
2023
Q4
$2.73M Sell
299,752
-17,571
-6% -$111K ﹤0.01% 2713
2023
Q3
$1.75M Sell
317,323
-286,838
-47% -$2.3M ﹤0.01% 2881
2023
Q2
$5.16M Buy
604,161
+347,911
+136% +$3.12M ﹤0.01% 2324
2023
Q1
$2.35M Buy
256,250
+373
+0.1% +$4.01K ﹤0.01% 2766
2022
Q4
$2.61M Sell
255,877
-28,074
-10% -$377K ﹤0.01% 2694
2022
Q3
$4.18M Buy
283,951
+7,749
+3% +$101K ﹤0.01% 2349
2022
Q2
$2.96M Buy
+276,202
New +$2.75M ﹤0.01% 2621
2021
Q4
Sell
-87,634
Closed -$1.88M 3976
2021
Q3
$1.88M Buy
+87,634
New +$2.06M ﹤0.01% 2896

Other funds holding CTKB

Ameriprise's CTKB Position: Q1 2026 in Review

Ameriprise reduced its Cytek Biosciences (CTKB) stake by 7.4% in Q1 2026, selling an estimated $71K and leaving 187,270 shares worth $818K. The position accounts for ﹤0.01% of the portfolio, ranked #3393.

Ameriprise first reported a position in CTKB in Q3 2021 and has held it in 17 quarters since. The position peaked at $5.16M in Q2 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Ameriprise held 187,270 shares of Cytek Biosciences worth $818K as of Q1 2026.
  • Ameriprise sold 15,046 Cytek Biosciences shares in Q1 2026, an estimated $71K.
  • Cytek Biosciences made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3393 holding.
  • Ameriprise first reported a position in Cytek Biosciences in Q3 2021 and has held it in 17 quarters since.
  • Ameriprise's Cytek Biosciences position peaked at $5.16M in Q2 2023.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.